Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism
Authors' conclusion
In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.
Study context
- Population
- Patients ≥18 years with autoimmune thyroiditis, thyroid peroxidase antibody (TPOAb) ≥100 IU/mL, on levothyroxine (LT4) treatment332 completed
- Participants
- 412 patients
- Comparison
- Daily 200 μg selenium vs placebo, add-on to LT4, for 12 months
- Primary endpoint
- QoL by ThyPRO-39
- Follow-up
- 12 months
Methodological detailsmulticentre, double-blinded, placebo-controlled
- Multicentre
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
ThyPRO-39 composite score (linear mixed model)
Selenium
28.8
95% CI 24.5–33.6
Placebo
28.0
95% CI 24.5–33.1
P = 0.602
Further findings
TPOAb level · 12 months · lower with selenium
P = 0.016
Quality-of-life (QoL) by subgroups (disease duration, baseline ThyPRO-39 composite score, TPOAb level, selenium status)
- Stratification did not significantly change the results
TPOAb level · 12 months
- Lower TPOAb did not influence LT4 dosage or FT3/FT4 ratio
Original publication
Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. Eur Thyroid J. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →